ATE489090T1 - Verringerung von übergewicht oder fettsucht - Google Patents

Verringerung von übergewicht oder fettsucht

Info

Publication number: ATE489090T1
Authority: AT; Austria
Prior art keywords: obesity; reducing overweight; reduction; weight gain; overweight
Prior art date: 2006-11-02

Application number

AT07766498T

Other languages

English (en)

Inventor

Nagy Peter Literati

Zoltan Szilvassy

Kalman Tory

Laszlo Vigh

Kalman Takacs

Jozsef Mandl

Balazs Suemegi

Sandor Bernath

Attila Kolonics

Gabor Balogh

Janos Egri

Original Assignee

N Gene Res Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-02

Filing date

2007-07-23

Publication date

2010-12-15

2007-07-23 Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE489090T1 publication Critical patent/ATE489090T1/de

Links

208000008589 Obesity Diseases 0.000 title 1
206010033307 Overweight Diseases 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1
235000019786 weight gain Nutrition 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 abstract 1
ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000004584 weight gain Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Fats And Perfumes (AREA)
Pyridine Compounds (AREA)

AT07766498T 2006-11-02 2007-07-23 Verringerung von übergewicht oder fettsucht ATE489090T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US85611706P	2006-11-02	2006-11-02
US11/687,945 US7763601B2 (en)	2006-11-02	2007-03-19	Prevention and treatment of obesity
PCT/HU2007/000066 WO2008053256A1 (en)	2006-11-02	2007-07-23	Reduction of overweight or obesity

Publications (1)

Publication Number	Publication Date
ATE489090T1 true ATE489090T1 (de)	2010-12-15

Family

ID=38592002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07766498T ATE489090T1 (de)	2006-11-02	2007-07-23	Verringerung von übergewicht oder fettsucht

Country Status (19)

Country	Link
US (1)	US7763601B2 (de)
EP (1)	EP2089031B1 (de)
JP (1)	JP2010509199A (de)
KR (1)	KR20090082442A (de)
AT (1)	ATE489090T1 (de)
AU (1)	AU2007315931A1 (de)
BR (1)	BRPI0717867A2 (de)
CA (1)	CA2668382A1 (de)
DE (1)	DE602007010819D1 (de)
DK (1)	DK2089031T3 (de)
HR (1)	HRP20110023T1 (de)
IL (1)	IL198296A (de)
MX (1)	MX2009004538A (de)
NO (1)	NO20092025L (de)
PL (1)	PL2089031T3 (de)
PT (1)	PT2089031E (de)
RU (1)	RU2443417C2 (de)
SI (1)	SI2089031T1 (de)
WO (1)	WO2008053256A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (de)	2007-04-11	2020-08-12	Omeros Corporation	Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
US20160331729A9 (en)	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
WO2009074835A1 (en) *	2007-12-10	2009-06-18	N-Gene Research Laboratories Inc.	Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
HUP1100444A2 (en)	2011-08-17	2013-02-28	Pharma Gene Sa	Pharmaceutical composition
HUP1100445A2 (en)	2011-08-17	2013-02-28	Pharma Gene Sa	Pharmaceutical composition
HUP1800298A1 (hu)	2018-08-30	2020-05-28	N Gene Res Laboratories Inc	Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
DE102020003608A1 (de) *	2020-06-17	2021-12-23	Bernd Clement	Hemmstoffe von mARC1 zur Behandlung von Krankheiten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4187220A (en) *	1977-08-30	1980-02-05	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T.	New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
US4287220A (en) *	1980-02-19	1981-09-01	Frito-Lay, Inc.	Hull containing compositions
HU207988B (en) *	1988-10-20	1993-07-28	Biorex Kutato Fejlesztoe Kft	Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU9502843D0 (en) *	1995-09-29	1995-11-28	Livigene Ltd	Pharmaceutical composition
US6458371B1 (en) *	1995-12-22	2002-10-01	Medgene, Limited	Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
US6884424B2 (en) *	1995-12-22	2005-04-26	N-Gene Research Laboratories Inc.	Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
HU9701081D0 (en) *	1997-06-23	1997-08-28	Gene Research Lab Inc N	Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) *	1997-06-23	1999-05-28	Gene Res Lab Inc New York N	Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
WO2000007580A2 (en)	1998-08-03	2000-02-17	N-Gene Kutató Kft.	Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) *	1998-09-03	2004-04-15	Н-Гене Кутато Кфт.	НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
EP1408966B1 (de)	2001-07-17	2008-02-20	N-Gene Research Laboratories Inc.	Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
HUP0401177A2 (en)	2004-06-14	2007-09-28	N Gene Res Lab Inc	Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en)	2004-06-14	2007-09-28	N Gene Res Lab Inc	Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en)	2005-01-28	2006-11-28	Gene Res Lab N	Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
CN101534836B (zh)	2006-09-05	2011-09-28	彼帕科学公司	Parp抑制剂在制备治疗肥胖症的药物中的用途

2007
- 2007-03-19 US US11/687,945 patent/US7763601B2/en not_active Expired - Fee Related
- 2007-07-23 PL PL07766498T patent/PL2089031T3/pl unknown
- 2007-07-23 EP EP07766498A patent/EP2089031B1/de active Active
- 2007-07-23 PT PT07766498T patent/PT2089031E/pt unknown
- 2007-07-23 KR KR1020097011079A patent/KR20090082442A/ko not_active Ceased
- 2007-07-23 HR HR20110023T patent/HRP20110023T1/hr unknown
- 2007-07-23 AT AT07766498T patent/ATE489090T1/de active
- 2007-07-23 DE DE602007010819T patent/DE602007010819D1/de active Active
- 2007-07-23 DK DK07766498.5T patent/DK2089031T3/da active
- 2007-07-23 MX MX2009004538A patent/MX2009004538A/es active IP Right Grant
- 2007-07-23 BR BRPI0717867-0A patent/BRPI0717867A2/pt not_active IP Right Cessation
- 2007-07-23 RU RU2009119567/15A patent/RU2443417C2/ru not_active IP Right Cessation
- 2007-07-23 WO PCT/HU2007/000066 patent/WO2008053256A1/en not_active Ceased
- 2007-07-23 AU AU2007315931A patent/AU2007315931A1/en not_active Abandoned
- 2007-07-23 JP JP2009535137A patent/JP2010509199A/ja active Pending
- 2007-07-23 CA CA002668382A patent/CA2668382A1/en not_active Abandoned
- 2007-07-23 SI SI200730517T patent/SI2089031T1/sl unknown
2009
- 2009-04-22 IL IL198296A patent/IL198296A/en not_active IP Right Cessation
- 2009-05-25 NO NO20092025A patent/NO20092025L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US7763601B2 (en)	2010-07-27
RU2009119567A (ru)	2010-12-10
JP2010509199A (ja)	2010-03-25
EP2089031A1 (de)	2009-08-19
EP2089031B1 (de)	2010-11-24
BRPI0717867A2 (pt)	2013-10-29
SI2089031T1 (sl)	2011-04-29
US20080108673A1 (en)	2008-05-08
DE602007010819D1 (de)	2011-01-05
KR20090082442A (ko)	2009-07-30
AU2007315931A1 (en)	2008-05-08
PL2089031T3 (pl)	2011-05-31
PT2089031E (pt)	2011-02-24
MX2009004538A (es)	2009-05-22
HK1131737A1 (en)	2010-02-05
IL198296A0 (en)	2010-02-17
HRP20110023T1 (hr)	2011-04-30
IL198296A (en)	2011-09-27
WO2008053256A1 (en)	2008-05-08
DK2089031T3 (da)	2011-02-14
NO20092025L (no)	2009-06-02
CA2668382A1 (en)	2008-05-08
RU2443417C2 (ru)	2012-02-27

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 2089031

Country of ref document: EP

Publication	Publication Date	Title
ATE489090T1 (de)	2010-12-15	Verringerung von übergewicht oder fettsucht
TW200738725A (en)	2007-10-16	Unsaturated mTOR inhibitors
MY150661A (en)	2014-02-14	Pyridin-3-yl derivatives as immunomodulating agents
MY149853A (en)	2013-10-31	Pyridin-4-yl derivatives as immunomodulating agents
MY143407A (en)	2011-05-13	Indazole derivatives as inhibitors of hormone sensitive lipase
UA115320C2 (uk)	2017-10-25	Інгібітори кінази
WO2008142055A3 (en)	2010-04-22	Antiviral agents
MX337081B (es)	2016-02-10	Anticuerpo anti-nr10 y su uso.
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
NO20083708L (no)	2008-09-23	4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
JP2007506758A5 (ja)	2007-10-18	４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ−プロポキシ）−安息香酸誘導体および線溶系の障害、血栓症の治療用のｐａｉ−１阻害剤としての関連化合物
MX2012002528A (es)	2012-04-11	Agente terapeutico para trastornos del estado de animo.
NO20092024L (no)	2009-06-02	En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning
PH12014501278A1 (en)	2014-09-08	Kinase inhibitors
SG170796A1 (en)	2011-05-30	Methods for improving the pharmacokinetics of hiv integrase inhibitors
MX2009010483A (es)	2009-10-19	5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
UA97348C2 (en)	2012-02-10	HETEROCYCLIC NF-kB INHIBITORS
WO2011058336A3 (en)	2012-01-12	Tablet comprising gum arabic
WO2009106599A3 (en)	2009-12-03	Substituted piperidines as therapeutic compounds
TN2012000093A1 (en)	2013-09-19	Therapeutic agent for anxiety disorders
NO20090292L (no)	2009-01-26	Fenyleddiksyrederivater
UA96312C2 (ru)	2011-10-25	Применение о-(3-пиперидино-2-гидрокси-1-пропил)никотинамидоксима для уменьшения чрезмерной массы тела или ожирения
ZA200605302B (en)	2007-04-25	Use of pentadienoic acid derivatives for the treatment of hyperuricemia
UA101141C2 (ru)	2013-03-11	Способ улучшения фармакокинетики ингибиторов интегразы вич
UA59517U (ru)	2011-05-25	Фармацевтическая композиция для лечения больных опиоидной зависимостью